The oral drug obeldesivir protects nonhuman primates against lethal Ebola virus infection.

Obeldesivir (ODV; GS-5245) is an orally administered ester prodrug of the parent nucleoside GS-441524 that has broad spectrum antiviral activity inhibiting viral RNA-dependent RNA polymerases. We recently showed that ODV completely protects cynomolgus macaques against lethal infection with Sudan virus when given 24 hours after parenteral exposure. Here, we report that once daily oral ODV treatment of cynomolgus and rhesus macaques for 10 days confers 80 and 100% protection, respectively, against lethal Ebola virus infection when treatment is initiated 24 hours after mucosal (conjunctival) exposure.

Promoting Physical Activity to Cancer Survivors in Practice: Challenges and Solutions for Implementation.

: This study explored the challenges and solutions to the effective promotion of physical activity (PA) to cancer survivors in practice in Ireland amongst a variety of stakeholders, including healthcare professionals (HCPs), policy makers, community providers of cancer care, and academics. : Focus groups (n = 5) were conducted with participants (n = 40), including oncologists, oncology nurses, physiotherapists, cancer support centre managers, academics, consumers, cancer policy representatives, exercise specialists, community providers of exercise programmes, and a chartered psychologist. The data were analysed using reflexive thematic analysis.

Genomic factors limiting the diversity of Saccharomycotina plant pathogens.

The Saccharomycotina fungi have evolved to inhabit a vast diversity of habitats over their 400-million-year evolution. There are, however, only a few known fungal pathogens of plants in this subphylum, primarily belonging to the genera and . We compared the genomes of 12 plant-pathogenic Saccharomycotina strains to 360 plant-associated strains to identify features unique to the phytopathogens.

Improving the Infrastructure for Pediatric Medical Device Trials at Children's Hospitals.

The shortage of novel pediatric devices that accommodate the unique needs of children exists due to several scientific, clinical, regulatory, and financial barriers. This global unmet need is being addressed in the United States by multiple stakeholders including the Food and Drug Administration (FDA) and its Pediatric Device Consortia (PDC) grant program. One critical area of interest is the suboptimal medical device clinical trial infrastructure that currently exists in academic medical centers and compounded at children's hospitals.

Enhancing Hospital Throughput: A Multidisciplinary Approach to Facilitating Discharges in a Pediatric Setting.

Introduction: Recent postpandemic respiratory viral surges have highlighted challenges in inpatient capacity at children's hospitals. Our hospital identified a key bottleneck affecting our ability to accommodate patients: afternoon discharge clustering. We sought to improve throughput efficiency by increasing the percentage of patients discharged outside peak hours.